Search results for " lymphoma"

showing 10 items of 448 documents

Are blood donors an adequate control group to ascertain HCV prevalence in non-Hodgkin’s lymphoma patients?

2002

Blood donorSettore MED/09 - Medicina Internanon-Hodgkin’s lymphomaHCV prevalence
researchProduct

Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Thera…

2022

Simple Summary We present the long-term results of patients receiving allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory mantle cell lymphoma (R/R MCL) in the last 25 years in Spain. We conclude that allo-SCT may be a curative option in R/R MCL with a low cumulative incidence (CI) of relapse, although non-relapse mortality (NRM) is still high, which is mainly secondary to acute graft-versus-host disease (aGVHD). Results are better for fit patients, using HLA-identical (related or unrelated) or haploidentical related donors and without previous ASCT. However, the arrival of new highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegat…

CAR-T cell therapyCancer ResearchLimfomesMantle cell lymphomaAcute graft-versus-host diseaseTransplantation of organstarget therapyacute graft-versus-host diseasemantle cell lymphomaTarget therapyTrasplantament d'òrgansgraft-versus-lymphoma effectnon-relapse mortalityOncologyNon-relapse mortalityimmune system diseaseshemic and lymphatic diseasesallogeneic stem-cell transplantationmantle cell lymphoma; allogeneic stem-cell transplantation; non-relapse mortality; acute graft-versus-host disease; graft-versus-lymphoma effect; target therapy; CAR-T cell therapyLymphomasAllogeneic stem-cell transplantationCàncerGraft-versus-lymphoma effect
researchProduct

Abstract 3289: Microenvironment modulation and enhancement of cytotoxic therapy by the heparanase inhibitor Roneparstat against human B-non Hodgkin l…

2016

Abstract Background: The standard chemotherapy treatment for Non-Hodgkin lymphoma (NHL) consists in the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Because of the relevant treatment-related toxicity and the minor therapeutic effectiveness of CHOP therapy variants, the development of novel therapeutic approaches represents an urgent clinical need. Despite treatment with the anti-CD20 monoclonal antibody Rituximab and CHOP has led to favourable results for CD20+ lymphoma, many patients experienced drug resistance. Based on studies indicating that the malignant behaviour of tumors depends on the interactions between tumor and its microenvironment, we tested…

CD20Cancer ResearchVincristineTumor microenvironmentbiologybusiness.industryCancerAggressive lymphomaCHOPmedicine.diseaseLymphomaOncologyimmune system diseaseshemic and lymphatic diseasesImmunologymedicineCancer researchbiology.proteinRituximabbusinessmedicine.drugCancer Research
researchProduct

Linfomatosis intravascular de presentación pulmonar

2001

Se presenta un caso de linfomatosis intravascular cuyas primeras manifestaciones clínicas fueron síntomas pulmonares (tos no productiva, hipoxia y patrón radiológico reticulointersticial), seguidas de fiebre de origen desconocido y síndrome confusional. El diagnóstico se obtuvo mediante estudio histológico e inmunohistoquímico postmortem, observándose en el pulmón tabiques alveolares engrosados por la presencia de células atípicas en el interior de los capilares que también ocupaban las luces de pequeños vasos, evidenciándose de forma aislada salida de las mismas al estroma fibroso perivascular y peribronquial. Las técnicas inmunohistoquímicas sobre cortes en parafina revelaron en las célul…

CD20Pathologymedicine.medical_specialtyLungbiologybusiness.industryAtypical cellsLinfomatosis intravascularCD34respiratory systemrespiratory tract diseasesmedicine.anatomical_structureLinfomaPulmónInternal Medicinebiology.proteinIntravascular lymphomatosisMedicinePulmonary infiltratesmedicine.symptombusinessConfusionAnales de Medicina Interna
researchProduct

Angioimmunoblastic T-cell lymphoma

2008

Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive neoplasm clinically characterized by sudden onset of constitutional symptoms, lymphadenopathy, hepatosplenomegaly, frequent autoimmune phenomena, particularly hemolytic anemia and thrombocytopenia, and polyclonal hypergammaglobulinemia. The lymph node histological picture is also distinctive, constituted by a polymorphic infiltrate, a marked proliferation of high endothelial venules, and a dense meshwork of dentritic cells. The neoplastic CD4+ T-cells represent a minority of the lymph node cell population; its detection is facilitated by the aberrant expression of CD10. Almost all cases arbor an EBV infected B-cell populatio…

CD4-Positive T-LymphocytesMaleEpstein-Barr Virus InfectionsPathologyAutologous transplantHerpesvirus 4 HumanHepatosplenomegalyImmunosuppressive AgentEpstein-Barr Virus InfectionHypergammaglobulinemiaLymph nodeNon-Hodgkin lymphomaAngioimmunoblastic lymphomaB-Lymphocyteseducation.field_of_studyB-LymphocyteLymph NodeHematologyThalidomideSurvival RateTransplantation Autologoumedicine.anatomical_structureOncologyCD4-Positive T-LymphocyteFemaleNeprilysinmedicine.symptomImmunosuppressive AgentsHumanmedicine.medical_specialtyAngioimmunoblastic T-cell lymphomaPopulationHigh endothelial venulesDendritic CellLymphoma T-CellTransplantation AutologousmedicineHumanseducationCell Proliferationbusiness.industryPeripheral T-cell lymphomaDendritic Cellsmedicine.diseasePeripheral T-cell lymphomaLymphomaTransplantationImmunologyLymph NodesGeriatrics and GerontologybusinessStem Cell Transplantation
researchProduct

Differences in Dendritic Cell Activation and Distribution After Intravenous, Intraperitoneal, and Subcutaneous Injection of Lymphoma Cells in Mice

2007

Dendritic cells (DCs) are key antigen-presenting cells (APCs) for initiating immune responses. However, in recent years, several groups have shown the defective function of DCs in tumor-bearing mice and in cancer patients. Our aim was to study the effects of lymphoma on DC differentiation and maturation and to assess the input of the tumor microenvironment and intravasation of tumor cells on DC precursors. EL-4 lymphoma cells were administrated via different routes (intraperitoneal, subcutaneous, and intravenous) and DC phenotype was investigated. Bone marrow-derived DCs and APCs obtained from the spleen were examined by flow cytometry, and immunohistochemical analysis of lymphoma, lungs, l…

CD86Tumor microenvironmentCD40biologybusiness.industryhemic and immune systemschemical and pharmacologic phenomenaSpleenDendritic cellmedicine.diseasemedicine.anatomical_structureImmune systemImmunologybiology.proteinMedicinebusinessAnaplastic large-cell lymphomaCD80
researchProduct

Transmission of angioimmunoblastic T-cell lymphoma by bone marrow transplant

2014

Accidental transmission of lymphoma by bone marrow transplant is a rarely reported event [1–5], since candidates are only accepted for hematopoietic stem cell donation after a work-up that routinel...

Cancer ResearchAngioimmunoblastic T-cell lymphomaBone marrow transplantPathologymedicine.medical_specialtybusiness.industryTransmission (medicine)Hematopoietic stem cellHematologymedicine.diseaseLymphomamedicine.anatomical_structureOncologymedicinebusinessLeukemia & Lymphoma
researchProduct

SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL…

2021

Cancer ResearchBortezomibbusiness.industryHematologyGeneral Medicinechemistry.chemical_compoundPhase i iiOncologychemistryIbrutinibCancer researchmedicineRefractory Mantle Cell Lymphomabusinessmedicine.drugHematological Oncology
researchProduct

Abstract 4107: Targeted re-sequencing of neuroblastoma tumors reveals chromosomal rearrangements that involve the Anaplastic Lymphoma Kinase (ALK) ge…

2013

Abstract Neuroblastoma (NBL) is a cancer of early childhood arising from the developing sympathetic nervous system. NBL tumors display a broad clinical and biological heterogeneity, ranging from highly aggressive tumors with fatal outcome to tumors with spontaneous regression. Recurrent mutations are mainly only observed in Anaplastic Lymphoma Kinase (ALK), which is involved in the pathogenesis of both familiar and sporadic NBL. ALK encodes a tyrosine kinase receptor with importance in neuronal development and was initially characterized in anaplastic large cell lymphoma from a translocation leading to the NPM-ALK fusion protein. Subsequent studies show that additional ALK chimeras have bee…

Cancer ResearchChromosomal translocationBiologyAmpliconmedicine.diseaseFusion proteinMolecular biologyExonOncologyhemic and lymphatic diseasesNeuroblastomamedicineAnaplastic lymphoma kinaseKinase activityAnaplastic large-cell lymphomaCancer Research
researchProduct

From a Better Understanding of the Mechanisms of Action of Histone Deacetylases Inhibitors to the Progress of the Treatment of Malignant Lymphomas an…

2017

Background Notable progress has been made in chemo- and immunotherapy of B-cell lymphomas, but less in the treatment of T-cell lymphomas. Objective Histone deacetylases inhibitors are a potentially useful therapeutic mean, as an epigenetic dysregulation is present in lymphomas, and especially in T-cell types. We aimed to study the progress made in this area. Method A mini-review was achieved using the articles published in PubMed in the last two years and the new patents made in this field. Results Histone deacetylases inhibitors are involved in the derepression of tumor suppressor genes through a histone deacetylase-mediated transcriptional process. Their inhibition is followed by cell cyc…

Cancer ResearchDrug exportmedicine.medical_treatmentCellular differentiationAntineoplastic Agents010402 general chemistryLymphoma T-Cell01 natural sciencesHistone DeacetylasesRomidepsinPatents as TopicDrug DiscoveryPlasma Cell MyelomamedicineAnimalsHumansPharmacology (medical)Epigeneticsbiology010405 organic chemistrybusiness.industryDrug SynergismGeneral MedicineImmunotherapymedicine.diseasePeripheral T-cell lymphoma0104 chemical sciencesHistone Deacetylase InhibitorsHistoneOncologyDrug DesignImmunologyCancer researchbiology.proteinbusinessMultiple Myelomamedicine.drugRecent patents on anti-cancer drug discovery
researchProduct